NYSEAMERICAN:LCTX Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free LCTX Stock Alerts $1.05 -0.08 (-7.08%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$1.04▼$1.1250-Day Range N/A52-Week Range$0.84▼$1.61Volume1.84 million shsAverage Volume926,518 shsMarket Capitalization$198.24 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Lineage Cell Therapeutics alerts: Email Address Lineage Cell Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside510.3% Upside$6.50 Price TargetShort InterestBearish5.60% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingAcquiring Shares$7.10 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.13) to ($0.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.62 out of 5 stars 3.5 Analyst's Opinion Consensus RatingLineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLineage Cell Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted5.60% of the outstanding shares of Lineage Cell Therapeutics have been sold short.Short Interest Ratio / Days to CoverLineage Cell Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Lineage Cell Therapeutics has recently increased by 1.73%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLineage Cell Therapeutics does not currently pay a dividend.Dividend GrowthLineage Cell Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LCTX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Lineage Cell Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for LCTX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Lineage Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lineage Cell Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,100,002.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders28.10% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lineage Cell Therapeutics are expected to grow in the coming year, from ($0.13) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lineage Cell Therapeutics is -8.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lineage Cell Therapeutics is -8.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLineage Cell Therapeutics has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Lineage Cell Therapeutics Stock (NYSEAMERICAN:LCTX)Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.Read More LCTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LCTX Stock News HeadlinesMay 2, 2024 | businesswire.comLineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024April 30, 2024 | businesswire.comLineage Receives Grant From California Institute for Regenerative Medicine (CIRM)May 2, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 29, 2024 | businesswire.comLineage Announces Changes to Board of DirectorsApril 19, 2024 | finance.yahoo.com12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear ByApril 1, 2024 | finance.yahoo.comLineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate DevelopmentMarch 28, 2024 | msn.com5 Simple Wealth-Building Tips For This Generation's Forward-ThinkersMarch 19, 2024 | markets.businessinsider.comOptimistic Buy Rating for Lineage Cell Therapeutics Ahead of OpRegen Study Data ReleaseMay 2, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...March 18, 2024 | seekingalpha.comPuma Biotechnology dips after dismissal of its suit was granted by a federal judgeMarch 18, 2024 | finance.yahoo.com15 Best Anti-Aging Foods for Youthful SkinMarch 18, 2024 | finance.yahoo.comLineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor SymposiumMarch 18, 2024 | businesswire.comLineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor SymposiumMarch 14, 2024 | finance.yahoo.comBillionaire Ken Fisher and Corporate Insiders Are Buying These 10 StocksMarch 13, 2024 | finance.yahoo.comRG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation SummitMarch 11, 2024 | finance.yahoo.comRG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology MeetingMarch 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lineage Cell Therapeutics Amidst Promising Regenerative Therapy AdvancementsMarch 8, 2024 | markets.businessinsider.comOptimistic Buy Rating for Lineage Cell Therapeutics Amid Pipeline Progress and Strategic PartnershipsMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lineage Cell Therapeutics Amid Strong Financials and Promising OpRegen Therapy ResultsMarch 8, 2024 | insidermonkey.comLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | msn.comLCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023March 7, 2024 | finance.yahoo.comLineage Cell Therapeutics Inc. Reports Q4 and Full Year 2023 Financial ResultsMarch 7, 2024 | benzinga.comLineage Cell Therapeutics: Q4 Earnings InsightsMarch 7, 2024 | businesswire.comLineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | benzinga.comA Preview Of Lineage Cell Therapeutics's EarningsFebruary 29, 2024 | finance.yahoo.comLineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024February 14, 2024 | benzinga.comLineage Cell Therapeutics Stock (AMEX:LCTX), Analyst Ratings, Price Targets, PredictionsSee More Headlines Receive LCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/02/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSEAMERICAN:LCTX CUSIPN/A CIKN/A Webwww.lineagecell.com Phone(442) 287-8963Fax510-521-3389Employees68Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$7.00 Low Stock Price Target$6.00 Potential Upside/Downside+519.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,490,000.00 Net Margins-240.20% Pretax Margin-260.28% Return on Equity-31.95% Return on Assets-19.89% Debt Debt-to-Equity RatioN/A Current Ratio2.14 Quick Ratio2.14 Sales & Book Value Annual Sales$8.94 million Price / Sales22.17 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book3.00Miscellaneous Outstanding Shares188,800,000Free Float135,556,000Market Cap$198.24 million OptionableNot Optionable Beta1.39 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Brian M. Culley M.A. (Age 53)M.B.A., CEO, President & Director Comp: $944.15kMs. Jill Ann Howe (Age 47)CFO & Principal Financial and Accounting Officer Comp: $125.52kMr. George A. Samuel III (Age 43)J.D., General Counsel & Company Secretary Comp: $560.95kIoana C. HoneDirector of Investor RelationsMs. Brandi L. Roberts CPA (Age 50)M.B.A., Consultant Comp: $407.45kMr. William Annett MBA (Age 70)President & CEO of OncoCyte Corporation Comp: $53.2kDr. Rami Skaliter Ph.D. (Age 66)Chief Executive Officer of Cell Cure Neurosciences Ms. Alexandra HernandezSenior Director of Finance & ControllerDr. Harold D. Waitz (Age 82)Vice President of Regulatory Affairs & Quality Control Comp: $90kMore ExecutivesKey CompetitorsCandel TherapeuticsNASDAQ:CADLAdverum BiotechnologiesNASDAQ:ADVMOptheaNASDAQ:OPTSutro BiopharmaNASDAQ:STROInnate PharmaOTCMKTS:IPHYFView All CompetitorsInsiders & InstitutionsFifth Third Wealth Advisors LLCBought 20,000 shares on 4/16/2024Ownership: 0.011%DCF Advisers LLCBought 12,000 shares on 2/13/2024Ownership: 0.054%Don M BaileyBought 96,155 shares on 2/8/2024Total: $100,001.20 ($1.04/share)Broadwood Partners, L.P.Bought 6,730,770 shares on 2/6/2024Total: $7.00 M ($1.04/share)View All Insider TransactionsView All Institutional Transactions LCTX Stock Analysis - Frequently Asked Questions Should I buy or sell Lineage Cell Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lineage Cell Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LCTX shares. View LCTX analyst ratings or view top-rated stocks. What is Lineage Cell Therapeutics' stock price target for 2024? 2 equities research analysts have issued 1-year price objectives for Lineage Cell Therapeutics' stock. Their LCTX share price targets range from $6.00 to $7.00. On average, they expect the company's stock price to reach $6.50 in the next year. This suggests a possible upside of 510.3% from the stock's current price. View analysts price targets for LCTX or view top-rated stocks among Wall Street analysts. When is Lineage Cell Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our LCTX earnings forecast. How were Lineage Cell Therapeutics' earnings last quarter? Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) released its quarterly earnings data on Thursday, March, 7th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.04. The company had revenue of $2.09 million for the quarter, compared to analyst estimates of $4.74 million. Lineage Cell Therapeutics had a negative trailing twelve-month return on equity of 31.95% and a negative net margin of 240.20%. What other stocks do shareholders of Lineage Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lineage Cell Therapeutics investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Enerplus (ERF), KushCo (KSHB) and Zosano Pharma (ZSAN). Who are Lineage Cell Therapeutics' major shareholders? Lineage Cell Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Fifth Third Wealth Advisors LLC (0.01%). Insiders that own company stock include Angus C Russell, Brian M Culley, Broadwood Partners, LP, Dipti Amin, Don M Bailey, Gary S Hogge and Michael H Mulroy. View institutional ownership trends. How do I buy shares of Lineage Cell Therapeutics? Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:LCTX) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTruth about Trump you’ve never heardPorter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsAI “wealth window” is closing June 25thParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.